Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931146 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL826755 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL7911543 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL826376 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL2702010 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL16487196 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL345583 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL22276615 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL22276602 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL8002115 | 1.00 | TDP1 (0.69) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118078995-B | Dual-targeting high-water-solubility micromolecular boron drug as well as preparation method and application thereof | 东莞市人民医院 | 2024-08-23 | — | — | CN | claimed |
| CN-118078995-A | Dual-targeting high-water-solubility micromolecular boron drug as well as preparation method and application thereof | 东莞市人民医院 | 2024-05-28 | — | — | CN | claimed |
| CN-114682309-B | Chip, method for producing a chip and use of a chip | 深圳华大生命科学研究院 | 2024-04-09 | — | — | CN | claimed |
| CN-117362387-A | Benzenesulfonamide piperazinone glycine derivative as well as preparation method and application thereof | 山东大学 | 2024-01-09 | — | — | CN | claimed |
| CN-116411354-A | Gene chip with modified surface of solid phase carrier | 深圳华大生命科学研究院 | 2023-07-11 | — | — | CN | claimed |
| CN-114682309-A | Chip, method for preparing chip and use of chip | 深圳华大生命科学研究院 | 2022-07-01 | — | — | CN | claimed |
| CN-112770782-A | Sustained delivery of angiopoietin-like 3 polypeptides | 诺华股份有限公司 | 2021-05-07 | — | — | CN | claimed |
| CN-110603060-A | Sustained release delivery system comprising traceless linker | 诺华股份有限公司 | 2019-12-20 | — | — | CN | claimed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-0494248-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-07-15 | — | — | EP | disclosed |
| US-5039805-A | Novel benzoic and phenylacetic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1991-08-13 | — | — | US | disclosed |
| WO-1991004746-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| EP-0372486-A2 | Benzoic-acid phenylacetic-acid derivatives, their preparation and their use as medicines | F. HOFFMANN-LA ROCHE AG (CH) | 1990-06-13 | — | — | EP | disclosed |
| US-4161521-A | Somatostatin analogs | MERCK & CO., INC. (US) | 1979-07-17 | — | — | US | disclosed |
| US-4133805-A | INHIBIT RELEASE OR PITUITARY GROWTH HORMONE, GLUCAGON, AND INSULIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | TDP1 3952/4885MEN1 3960/4885GAA 3879/4885 |
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | TTR, CRYAA, BCL6 | TDP1 1226/4885MEN1 2701/4885GAA 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.